Answers are grounded in this paper and cite their sources.
Review highlights emerging extended half-life factors and subcutaneous non-factor treatments for hemophilia, indicating potential relief from frequent intravenous infusion burdens.
Hemophilia is a single gene disorder and as a genetical coagulation system problem it is a life-long bleeding disorder. Even though routine treatment modalities as plasma-derived and then recombinant factor concentrates available for last 50 years, unmet needs is continuing for hemophilia therapy. Gold standart treatment is regularly prophylactic FVIII/FIX infusions. However, life-long and frequent intra-venous infusions become medical burden for patients and families. New agents as enhanced half-life (EHL) factor concentrates and non-factor therapies which are able to be used subcutaneously are very hopeful. In this review, EHL factor concentrates, FVIII mimetic agents and re-balancing therapies will be discussed. Although celluler gene therapy is very hopeful and successful phase-3 studies are reported, gene therapy for hemophilia will not be mentioned in this review.
No takes yet. Share an insight, caveat, or question.
Kaan Kavaklı (2022) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: